Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome, Italy.
Information Technology Service, Istituto Superiore di Sanità, Rome, Italy.
J Endocrinol Invest. 2019 Jul;42(7):769-777. doi: 10.1007/s40618-018-0980-3. Epub 2018 Nov 15.
In Italy, the utilization and the reimbursement of Growth Hormone (rGH) therapy by the National Health System (Servizio Sanitario Nazionale) are regulated by the "Note #39" included in the "Notes for the use of drugs" by the Italian Medicines Agency (AIFA), which are published in the Official Gazette, thus having the force of law. The "Note #39" establishes the diagnosis for which the reimbursement is granted and confirms the assignment of the national health surveillance on the use of GH therapy to the Italian National Institute of Health, requesting its computerization.
The aim of this work was to realize a dedicated electronic Clinical Report Form based on the mandatory data requested by the Note #39 and allowing the online reporting of the rGH prescriptions by the regional accredited centers.
This interface is at the base of the national database of the Italian Registry of GH Treatment, which allows obtaining and managing correct and complete data to provide public health surveillance on GH therapy, both at national and local levels, necessary for policymakers decisions. In addition, this national database could be a useful instrument for improving knowledge about aspects of this treatment still under discussion.
在意大利,国家卫生系统(Servizio Sanitario Nazionale)对生长激素(rGH)治疗的使用和报销受意大利药品管理局(AIFA)“Notes for the use of drugs”中包含的“Note #39”监管,该“Note #39”规定了报销的诊断,并确认将 GH 治疗的国家卫生监督分配给意大利国家卫生研究所,要求对其进行计算机化管理。
本工作旨在基于“Note #39”要求的强制性数据,创建专用的电子临床报告表,并允许区域认证中心在线报告 rGH 处方。
该接口是意大利 GH 治疗登记处国家数据库的基础,该数据库允许获得和管理正确和完整的数据,以在国家和地方层面上提供 GH 治疗的公共卫生监督,这是政策制定者决策所必需的。此外,该国家数据库可以成为改善对该治疗仍在讨论中的方面的认识的有用工具。